search
Back to results

Preventing OUD in Justice-Involved Youth (POST)

Primary Purpose

Substance Use Disorders, Recidivism

Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Adolescent Community Reinforcement Approach
Assertive Continuing Care
Trauma Affect Regulation Guide for Education and Therapy
Motivational Interviewing
Opioid Education Workbook
Sponsored by
Seattle Children's Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Substance Use Disorders focused on measuring Juvenile Rehabilitation, Adolescent, Young Adult, Juvenile Justice, Opioids, Opioid Use Disorder, Substance Use, Prevention, Recidivism, Substance Use Disorder, Cost Effectiveness, Benefit Cost Analysis

Eligibility Criteria

15 Years - 25 Years (Child, Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age 15-25
  • Leaving a Washington State detention facility or group home in the next 5-7 months
  • Able to speak/understand English sufficiently to participate meaningfully in the intervention and assessments

Exclusion Criteria:

  • Diagnosed with a moderate or severe Opioid Use Disorder
  • Has a learning or mental health issue severe enough that they are unable to participate meaningfully in the intervention and assessments (e.g. schizophrenia or severe developmental disability)

Sites / Locations

  • Washington State Department of Children, Youth and FamiliesRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Enhanced A-CRA (E-ACRA)

Assertive Community Support (ACS)

Arm Description

Higher intensity

Lower intensity

Outcomes

Primary Outcome Measures

Number of substance use episodes
Self-reported number of episodes of substance use on days any substance was used in the past 30 days based on questions developed in collaboration with coordinating center Research Triangle Institute and other grantees.
Number of substance use episodes
Self-reported number of episodes of substance use on days any substance was used in the past 30 days based on questions developed in collaboration with coordinating center Research Triangle Institute and other grantees.
Number of substance use episodes
Self-reported number of episodes of substance use on days any substance was used in the past 30 days based on questions developed in collaboration with coordinating center Research Triangle Institute and other grantees.
Frequency of substance use episodes
Self-reported number of days of any substance use in the past 30 days based on questions developed in collaboration with coordinating center Research Triangle Institute and other grantees.
Frequency of substance use episodes
Self-reported number of days of any substance use in the past 30 days based on questions developed in collaboration with coordinating center Research Triangle Institute and other grantees.
Frequency of substance use episodes
Self-reported number of days of any substance use in the past 30 days based on questions developed in collaboration with coordinating center Research Triangle Institute and other grantees.
Rate of Recidivism
Convictions in either the juvenile or adult justice system for offenses within an 18-month period
Rate of Recidivism
Convictions in either the juvenile or adult justice system for offenses within an 18-month period

Secondary Outcome Measures

Number of new opioid users
Number of participants who ever used opioids among those who had never used at baseline based on questions developed in collaboration with coordinating center Research Triangle Institute and other grantees.
Number of participants with escalated opioid use
Number of participants whose days of use increased compared to prior measure based on questions developed in collaboration with coordinating center Research Triangle Institute and other grantees.
Number of participants with escalated opioid use
Number of participants whose days of use increased compared to prior measure based on questions developed in collaboration with coordinating center Research Triangle Institute and other grantees.
Number of participants with escalated opioid use
Number of participants whose days of use increased compared to prior measure based on questions developed in collaboration with coordinating center Research Triangle Institute and other grantees.
Number of use episodes of specific substances (e.g. opioids, marijuana, etc.)
Self-reported number of episodes of use of a specific substance on days that substance was used in the past 30 days based on questions developed in collaboration with coordinating center Research Triangle Institute and other grantees.
Number of use episodes of specific substances (e.g. opioids, marijuana, etc.)
Self-reported number of episodes of use of a specific substance on days that substance was used in the past 30 days based on questions developed in collaboration with coordinating center Research Triangle Institute and other grantees.
Number of use episodes of specific substances (e.g. opioids, marijuana, etc.)
Self-reported number of episodes of use of a specific substance on days that substance was used in the past 30 days based on questions developed in collaboration with coordinating center Research Triangle Institute and other grantees.
Frequency of use of specific substances (e.g. opioids, marijuana, etc.)
Self-reported number of days a specific substance was used in the past 30 days based on questions developed in collaboration with coordinating center Research Triangle Institute and other grantees.
Frequency of use of specific substances (e.g. opioids, marijuana, etc.)
Self-reported number of days a specific substance was used in the past 30 days based on questions developed in collaboration with coordinating center Research Triangle Institute and other grantees.
Frequency of use of specific substances (e.g. opioids, marijuana, etc.)
Self-reported number of days a specific substance was used in the past 30 days based on questions developed in collaboration with coordinating center Research Triangle Institute and other grantees.
Number of instances of overdose among non-opioid users
Self-reported number of instances of overdose
Number of instances of overdose among non-opioid users
Self-reported number of instances of overdose
Problematic substance use
Self-reported substance use beyond a developmentally appropriate threshhold. For those under age 21, problematic use is defined as any of the following: 1) use of alcohol or marijuana several times a week or more; 2) use of any other drugs, or dabbing marijuana 1-2 times per month or more; 3) score on CRAFFT of 2 or more (https://crafft.org). For those age 21 and older, problematic use is defined as any of the following: 1) use of alcohol or marijuana every day or most days each week; 2) use of any other drugs, or dabbing marijuana 1-2 times per month or more; 3) score on CRAFFT of 2 or more (https://crafft.org)
Problematic substance use
Self-reported substance use beyond a developmentally appropriate threshhold. For those under age 21, problematic use is defined as any of the following: 1) use of alcohol or marijuana several times a week or more; 2) use of any other drugs, or dabbing marijuana 1-2 times per month or more; 3) score on CRAFFT of 2 or more (https://crafft.org). For those age 21 and older, problematic use is defined as any of the following: 1) Use of alcohol or marijuana every day or most days each week; 2) Use of any other drugs, or dabbing marijuana 1-2 times per month or more; 3) Score on CRAFFT of 2 or more (https://crafft.org)
Cost of ACRA Lite (medium intensity arm) per participant
Cost in US Dollars of ACRA Lite intervention from study's Cost Analysis program
Cost of Enhanced ACRA (high intensity arm) per participant
Cost in US Dollars of Enhanced ACRA intervention from study's Cost Analysis program
Cost of Education Workbook (low intensity arm) per participant
Cost in US Dollars of Education Workbook intervention from study's Cost Analysis program

Full Information

First Posted
February 11, 2021
Last Updated
October 24, 2022
Sponsor
Seattle Children's Hospital
Collaborators
University of Washington, Washington State Department of Children, Youth and Families, Michigan State University, RTI International, National Institute on Drug Abuse (NIDA)
search

1. Study Identification

Unique Protocol Identification Number
NCT04901312
Brief Title
Preventing OUD in Justice-Involved Youth
Acronym
POST
Official Title
Identifying an Effective and Cost Beneficial Approach to Preventing OUD in Justice-Involved Youth
Study Type
Interventional

2. Study Status

Record Verification Date
October 2022
Overall Recruitment Status
Recruiting
Study Start Date
January 20, 2021 (Actual)
Primary Completion Date
August 31, 2024 (Anticipated)
Study Completion Date
August 31, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Seattle Children's Hospital
Collaborators
University of Washington, Washington State Department of Children, Youth and Families, Michigan State University, RTI International, National Institute on Drug Abuse (NIDA)

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The United States is experiencing an opioid epidemic. Sadly, opioid-related fatalities are on the rise, causing profound emotional, financial, and cultural impacts. One way to reduce these negative impacts is to prevent people from developing opioid use problems in the first place. Research shows that youth and young adults in the juvenile justice system have higher rates of opioid use disorder than other young people in the general population. The POST Study seeks develop, implement and evaluate the effectiveness and cost of 2 opioid use prevention programs of varying intensities. The prevention programs are designed specifically for youth and young adults living in justice settings. It is implemented during the time they are transitioning out of incarceration and back into the community. The research team hopes their results will help justice settings implement their own effective opioid prevention programs in the future.
Detailed Description
Non-prescription opioid use in adolescents and young adults is epidemic in our country and overdose-related fatalities are rising. Adolescents and young adults in justice settings have some of the highest rates of opioid use disorder (OUD), with national rates approaching 20%. The majority of these youth and young adults engage in problematic non-opioid substance use, which is a critical risk factor for OUD. Non-opioid substance use disorders (SUDs) and OUD, in turn, are two of the most important predictors of subsequent re-involvement in juvenile or criminal justice systems. In this study, researchers at Seattle Children's Research Institute, the University of Washington, Michigan State University, and Washington State Juvenile Rehabilitation/Department of Children Youth and Families will collaboratively develop and test an evaluation of OUD prevention interventions of varying intensities based on the Adolescent Community Reinforcement Approach with Assertive Continuing Care (ACRA+ACC). Multiple studies have established effectiveness of ACRA+ACC in reducing SUD; however, none has evaluated it as an OUD prevention strategy. SUD is incredibly common and costly among youth and young adults involved in juvenile justice systems. Thus, ACRA+ACC-based approaches are likely to be effective and cost-beneficial OUD prevention strategies for this group. Investigators seek to determine the optimal intensity of an ACRA+ACC-based OUD prevention intervention for AYAJS with and without non-opioid SUD, as these groups are likely to have differing prevention needs. To do so, they will use a Sequential Multiple Assignment Randomized Trial (SMART) study design to construct high-quality adaptive interventions with ACRA+ACC-based OUD prevention strategies of different intensity levels among youth with and without SUD. Based on self-reported substance use at 1 month post-release, participants may be re-randomized into another study arm. This will both address treatment need and provide data for subsequent effectiveness and cost analyses. In Phase I of this study, researchers collaboratively planned for a SMART experiment, i.e.: finalize infrastructure, recruitment, intervention, and data collection procedures; and create infrastructure for the possibility of future implementation of effective interventions. They conducted a pilot with 31 participants to assess feasibility of protocols and procedures, recruitment, engagement, and retention strategies in anticipation of a future larger trial. Phase I started in January 2021. In Phase II of this study, currently ongoing, researchers are conducting a SMART trial with 215 AYAJS aged 15-25, with or without SUD but without moderate or severe OUD, to evaluate ACRA/ACC-based interventions of various intensity levels for youth. They will also conduct cost, cost-effectiveness, and benefit-cost analyses to understand the relationships between intervention costs and outcomes. Phase II started in August 2021.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Substance Use Disorders, Recidivism
Keywords
Juvenile Rehabilitation, Adolescent, Young Adult, Juvenile Justice, Opioids, Opioid Use Disorder, Substance Use, Prevention, Recidivism, Substance Use Disorder, Cost Effectiveness, Benefit Cost Analysis

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Sequential Assignment
Model Description
Sequential Multiple Assignment Randomized Trial
Masking
Outcomes Assessor
Masking Description
The Outcomes Assessor (data collection team) will not be aware of the participant's study arm when they collect survey data.
Allocation
Randomized
Enrollment
215 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Enhanced A-CRA (E-ACRA)
Arm Type
Experimental
Arm Description
Higher intensity
Arm Title
Assertive Community Support (ACS)
Arm Type
Experimental
Arm Description
Lower intensity
Intervention Type
Behavioral
Intervention Name(s)
Adolescent Community Reinforcement Approach
Other Intervention Name(s)
A-CRA, ACRA
Intervention Description
The Adolescent Community Reinforcement Approach (A-CRA) is a developmentally-appropriate behavioral treatment for youth and young adults ages 12 to 24 years old with substance use disorders. A-CRA seeks to increase the family, social, and educational/vocational reinforces to support recovery. This intervention has been implemented in outpatient, intensive outpatient, and residential treatment settings. A-CRA includes guidelines for three types of sessions: individuals alone, parents/caregivers alone, and individuals and parents/caregivers together. According to the individual's needs and self-assessment of happiness in multiple life areas, clinicians choose from a variety of A-CRA procedures that address, for example, problem-solving skills to cope with day-to-day stressors, communication skills, and active participation in positive social and recreational activities with the goal of improving life satisfaction and eliminating alcohol and substance use problems.
Intervention Type
Behavioral
Intervention Name(s)
Assertive Continuing Care
Other Intervention Name(s)
ACC
Intervention Description
Assertive Continuing Care (ACC) uses Community Reinforcement Approach (CRA) procedures, home visits, and case management for individuals following an initial substance use treatment episode. It stresses rapid initiation of services after discharge from residential, intensive outpatient, or regular outpatient treatment in order to promote recovery and prevent relapse.
Intervention Type
Behavioral
Intervention Name(s)
Trauma Affect Regulation Guide for Education and Therapy
Other Intervention Name(s)
T4, TARGET
Intervention Description
Trauma Affect Regulation: Guide for Education and Therapy is a psychosocial intervention for traumatized adolescents, adults, and families, and for workforce and organizational responses to secondary/vicarious traumatization. T4, the 4-session version, provides education about the impact of complex traumatic stress on the brain's stress response system, and strengths-based practical skills for re-setting the trauma-related alarm/survival reactions that occur in complex PTSD.
Intervention Type
Behavioral
Intervention Name(s)
Motivational Interviewing
Other Intervention Name(s)
MI
Intervention Description
Motivational interviewing is a collaborative, person-centered form of guiding to elicit and strengthen motivation for change.
Intervention Type
Other
Intervention Name(s)
Opioid Education Workbook
Other Intervention Name(s)
Education
Intervention Description
A digital workbook designed to be completed on a computer in about 2 hours. Topics include opioid use, opioid use disorder, and prevention and treatment of opioid overdose.
Primary Outcome Measure Information:
Title
Number of substance use episodes
Description
Self-reported number of episodes of substance use on days any substance was used in the past 30 days based on questions developed in collaboration with coordinating center Research Triangle Institute and other grantees.
Time Frame
Last 30 days at 2 months post-release (Phase I)
Title
Number of substance use episodes
Description
Self-reported number of episodes of substance use on days any substance was used in the past 30 days based on questions developed in collaboration with coordinating center Research Triangle Institute and other grantees.
Time Frame
Last 30 days at 3 months post-release (Phase II)
Title
Number of substance use episodes
Description
Self-reported number of episodes of substance use on days any substance was used in the past 30 days based on questions developed in collaboration with coordinating center Research Triangle Institute and other grantees.
Time Frame
Last 30 days at 6 months post-release (Phase II)
Title
Frequency of substance use episodes
Description
Self-reported number of days of any substance use in the past 30 days based on questions developed in collaboration with coordinating center Research Triangle Institute and other grantees.
Time Frame
Last 30 days at 2 months post-release (Phase I)
Title
Frequency of substance use episodes
Description
Self-reported number of days of any substance use in the past 30 days based on questions developed in collaboration with coordinating center Research Triangle Institute and other grantees.
Time Frame
Last 30 days at 3 months post-release (Phase II)
Title
Frequency of substance use episodes
Description
Self-reported number of days of any substance use in the past 30 days based on questions developed in collaboration with coordinating center Research Triangle Institute and other grantees.
Time Frame
Last 30 days at 6 months post-release (Phase II)
Title
Rate of Recidivism
Description
Convictions in either the juvenile or adult justice system for offenses within an 18-month period
Time Frame
12 months post-release
Title
Rate of Recidivism
Description
Convictions in either the juvenile or adult justice system for offenses within an 18-month period
Time Frame
18 months post-release
Secondary Outcome Measure Information:
Title
Number of new opioid users
Description
Number of participants who ever used opioids among those who had never used at baseline based on questions developed in collaboration with coordinating center Research Triangle Institute and other grantees.
Time Frame
6 months post-release (Phase II)
Title
Number of participants with escalated opioid use
Description
Number of participants whose days of use increased compared to prior measure based on questions developed in collaboration with coordinating center Research Triangle Institute and other grantees.
Time Frame
Last 30 days at 2 months post-release vs. before incarceration (Phase I)
Title
Number of participants with escalated opioid use
Description
Number of participants whose days of use increased compared to prior measure based on questions developed in collaboration with coordinating center Research Triangle Institute and other grantees.
Time Frame
Last 30 days at 3 months post-release vs. before incarceration (Phase II)
Title
Number of participants with escalated opioid use
Description
Number of participants whose days of use increased compared to prior measure based on questions developed in collaboration with coordinating center Research Triangle Institute and other grantees.
Time Frame
Last 30 days at 6 months post-release vs. at 3 months post-release (Phase II)
Title
Number of use episodes of specific substances (e.g. opioids, marijuana, etc.)
Description
Self-reported number of episodes of use of a specific substance on days that substance was used in the past 30 days based on questions developed in collaboration with coordinating center Research Triangle Institute and other grantees.
Time Frame
Last 30 days at 2 months post-release (Phase I)
Title
Number of use episodes of specific substances (e.g. opioids, marijuana, etc.)
Description
Self-reported number of episodes of use of a specific substance on days that substance was used in the past 30 days based on questions developed in collaboration with coordinating center Research Triangle Institute and other grantees.
Time Frame
Last 30 days at 3 months post-release (Phase II)
Title
Number of use episodes of specific substances (e.g. opioids, marijuana, etc.)
Description
Self-reported number of episodes of use of a specific substance on days that substance was used in the past 30 days based on questions developed in collaboration with coordinating center Research Triangle Institute and other grantees.
Time Frame
Last 30 days at 6 months post-release (Phase II)
Title
Frequency of use of specific substances (e.g. opioids, marijuana, etc.)
Description
Self-reported number of days a specific substance was used in the past 30 days based on questions developed in collaboration with coordinating center Research Triangle Institute and other grantees.
Time Frame
Last 30 days at 2 months post-release (Phase I)
Title
Frequency of use of specific substances (e.g. opioids, marijuana, etc.)
Description
Self-reported number of days a specific substance was used in the past 30 days based on questions developed in collaboration with coordinating center Research Triangle Institute and other grantees.
Time Frame
Last 30 days at 3 months post-release (Phase II)
Title
Frequency of use of specific substances (e.g. opioids, marijuana, etc.)
Description
Self-reported number of days a specific substance was used in the past 30 days based on questions developed in collaboration with coordinating center Research Triangle Institute and other grantees.
Time Frame
Last 30 days at 6 months post-release (Phase II)
Title
Number of instances of overdose among non-opioid users
Description
Self-reported number of instances of overdose
Time Frame
Last 30 days at 3 months post-release (Phase II)
Title
Number of instances of overdose among non-opioid users
Description
Self-reported number of instances of overdose
Time Frame
Last 30 days at 6 months post-release (Phase II)
Title
Problematic substance use
Description
Self-reported substance use beyond a developmentally appropriate threshhold. For those under age 21, problematic use is defined as any of the following: 1) use of alcohol or marijuana several times a week or more; 2) use of any other drugs, or dabbing marijuana 1-2 times per month or more; 3) score on CRAFFT of 2 or more (https://crafft.org). For those age 21 and older, problematic use is defined as any of the following: 1) use of alcohol or marijuana every day or most days each week; 2) use of any other drugs, or dabbing marijuana 1-2 times per month or more; 3) score on CRAFFT of 2 or more (https://crafft.org)
Time Frame
Last 30 days at 6 months post-release (Phase II)
Title
Problematic substance use
Description
Self-reported substance use beyond a developmentally appropriate threshhold. For those under age 21, problematic use is defined as any of the following: 1) use of alcohol or marijuana several times a week or more; 2) use of any other drugs, or dabbing marijuana 1-2 times per month or more; 3) score on CRAFFT of 2 or more (https://crafft.org). For those age 21 and older, problematic use is defined as any of the following: 1) Use of alcohol or marijuana every day or most days each week; 2) Use of any other drugs, or dabbing marijuana 1-2 times per month or more; 3) Score on CRAFFT of 2 or more (https://crafft.org)
Time Frame
Last 30 days at 3 months post-release (Phase II)
Title
Cost of ACRA Lite (medium intensity arm) per participant
Description
Cost in US Dollars of ACRA Lite intervention from study's Cost Analysis program
Time Frame
3 months post-release
Title
Cost of Enhanced ACRA (high intensity arm) per participant
Description
Cost in US Dollars of Enhanced ACRA intervention from study's Cost Analysis program
Time Frame
3 months post-release
Title
Cost of Education Workbook (low intensity arm) per participant
Description
Cost in US Dollars of Education Workbook intervention from study's Cost Analysis program
Time Frame
at release
Other Pre-specified Outcome Measures:
Title
Participant attendance
Description
Number of sessions attended
Time Frame
2 months post-release (Phase I)
Title
Participant attendance
Description
Number of sessions attended
Time Frame
3 months post-release (Phase II)
Title
Participant satisfaction
Description
Self-reported satisfaction with coach on a scale of very satisfied, somewhat satisfied, not very satisfied, not at all satisfied
Time Frame
2 months post-release (Phase I)
Title
Participant satisfaction
Description
Self-reported satisfaction with coach on a scale of very satisfied, somewhat satisfied, not very satisfied, not at all satisfied
Time Frame
3 months post-release (Phase II)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
15 Years
Maximum Age & Unit of Time
25 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age 15-25 Leaving a Washington State detention facility or group home in the next 5-7 months Able to speak/understand English sufficiently to participate meaningfully in the intervention and assessments Exclusion Criteria: Diagnosed with a moderate or severe Opioid Use Disorder Has a learning or mental health issue severe enough that they are unable to participate meaningfully in the intervention and assessments (e.g. schizophrenia or severe developmental disability)
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Katie Albertson
Phone
206-568-5546
Email
katie.albertson@seattlechildrens.org
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kym Ahrens, MD MPH
Organizational Affiliation
Seattle Children's Hospital
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Kevin Haggerty, MSW PhD
Organizational Affiliation
University of Washington
Official's Role
Principal Investigator
Facility Information:
Facility Name
Washington State Department of Children, Youth and Families
City
Olympia
State/Province
Washington
ZIP/Postal Code
98504
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Robert Hopkins
Phone
360-701-4615
Email
robert.hopkins@dcyf.wa.gov
First Name & Middle Initial & Last Name & Degree
Ted Ryle, MSW MA

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
Individual participant data will be shared with other researchers in the HEAL Prevention Collaborative. Further specific detail will be reported as the plans are finalized.
IPD Sharing Time Frame
Within four weeks of acceptance by a journal, we will deposit electronic copies of publications in PubMed Central. Publications will be made publicly available immediately without any embargo period.
Citations:
PubMed Identifier
27614657
Citation
Martins SS, Segura LE, Santaella-Tenorio J, Perlmutter A, Fenton MC, Cerda M, Keyes KM, Ghandour LA, Storr CL, Hasin DS. Prescription opioid use disorder and heroin use among 12-34 year-olds in the United States from 2002 to 2014. Addict Behav. 2017 Feb;65:236-241. doi: 10.1016/j.addbeh.2016.08.033. Epub 2016 Aug 30. No abstract available.
Results Reference
background
Citation
Understanding the epidemic. Retrieved from https://www.cdc.gov/drugoverdose/epidemic/index.html. Accessed 3-2-2019.2018.
Results Reference
background
Citation
Forsyth CJ, Biggar RW, Chen J, Burstein K. Examining heroin use and prescription opioid misuse among adolescents. Criminal Justice Studies: A Critical Journal of Crime, Law & Society 2017;30:320-9.
Results Reference
background
PubMed Identifier
15963906
Citation
Sung HE, Richter L, Vaughan R, Johnson PB, Thom B. Nonmedical use of prescription opioids among teenagers in the United States: trends and correlates. J Adolesc Health. 2005 Jul;37(1):44-51. doi: 10.1016/j.jadohealth.2005.02.013.
Results Reference
background
PubMed Identifier
22525786
Citation
Vaughn MG, Fu Q, Perron BE, Wu LT. Risk profiles among adolescent nonmedical opioid users in the United States. Addict Behav. 2012 Aug;37(8):974-7. doi: 10.1016/j.addbeh.2012.03.015. Epub 2012 Mar 27.
Results Reference
background
PubMed Identifier
30767596
Citation
Wojciechowski TW. Developmental Trajectories of Opioid Use Among Juvenile Offenders: An Epidemiological Examination of Group Characteristics and Criminological Risk Factors. Subst Use Misuse. 2019;54(7):1203-1213. doi: 10.1080/10826084.2019.1573837. Epub 2019 Feb 15.
Results Reference
background
Citation
Mulvey EP, Schubert CA, Chassin L. Substance Use and Offending in Serious Adolescent Offenders. In: Department of Justice OoJP, Office of Juvenile Justice and Delinquency Prevention., ed. Washington, DC: U.S. 2010.
Results Reference
background
Citation
Grisso T. Double jeopardy: adolescent offenders with mental disorders. Chicago: University of Chicago Press; 2004.
Results Reference
background
PubMed Identifier
23391856
Citation
Ghandour LA, El Sayed DS, Martins SS. Alcohol and illegal drug use behaviors and prescription opioids use: how do nonmedical and medical users compare, and does motive to use really matter? Eur Addict Res. 2013;19(4):202-10. doi: 10.1159/000345445. Epub 2013 Feb 7.
Results Reference
background
PubMed Identifier
29338770
Citation
Cheng T, Small W, Nosova E, Hogg B, Hayashi K, Kerr T, DeBeck K. Nonmedical prescription opioid use and illegal drug use: initiation trajectory and related risks among people who use illegal drugs in Vancouver, Canada. BMC Res Notes. 2018 Jan 16;11(1):35. doi: 10.1186/s13104-018-3152-9.
Results Reference
background
PubMed Identifier
30784952
Citation
Jones CM, McCance-Katz EF. Co-occurring substance use and mental disorders among adults with opioid use disorder. Drug Alcohol Depend. 2019 Apr 1;197:78-82. doi: 10.1016/j.drugalcdep.2018.12.030. Epub 2019 Feb 14.
Results Reference
background
PubMed Identifier
30335425
Citation
Scott T, Brown SL. Risks, strengths, gender, and recidivism among justice-involved youth: A meta-analysis. J Consult Clin Psychol. 2018 Nov;86(11):931-945. doi: 10.1037/ccp0000343.
Results Reference
background
Citation
The National Center for Addiction and Substance Abuse Research, Columbia University. Criminal Neglect: Substance Abuse, Juvenile Justice and The Children Left Behind. 2004.
Results Reference
background
Citation
Mulvey EP. Highlights From Pathways to Desistance: A Longitudinal Study of Serious Adolescent Offenders. 2011.
Results Reference
background
Citation
Godley SH, Smith JE, Meyers RJ, Godley MD. The Adolescent Community Reinforcement Approach: A Clinical Guide for Treating Substance Use Disorders. Normal, IL: Chestnut Health Systems; 2016.
Results Reference
background
Citation
Godley SH, Meyers RJ, Smith JE, et al. The Adolescent Community Reinforcement Approach for Adolescent Cannabis Users (Cannabis Youth Treatment (Cyt) Series) - Volume 4. Rockville, MD.
Results Reference
background
PubMed Identifier
22661797
Citation
Ahrens KR, Dubois DL, Garrison M, Spencer R, Richardson LP, Lozano P. Qualitative exporation of relationships with important non-parental adults in the lives of youth in foster care. Child Youth Serv Rev. 2011 Jun 1;33(6):1012-1023. doi: 10.1016/j.childyouth.2011.01.006.
Results Reference
background
PubMed Identifier
28282523
Citation
Godley MD, Passetti LL, Subramaniam GA, Funk RR, Smith JE, Meyers RJ. Adolescent Community Reinforcement Approach implementation and treatment outcomes for youth with opioid problem use. Drug Alcohol Depend. 2017 May 1;174:9-16. doi: 10.1016/j.drugalcdep.2016.12.029. Epub 2017 Feb 22.
Results Reference
background
PubMed Identifier
21443309
Citation
Godley SH, Hedges K, Hunter B. Gender and racial differences in treatment process and outcome among participants in the adolescent community reinforcement approach. Psychol Addict Behav. 2011 Mar;25(1):143-54. doi: 10.1037/a0022179.
Results Reference
background
PubMed Identifier
24462478
Citation
Godley SH, Hunter BD, Fernandez-Artamendi S, Smith JE, Meyers RJ, Godley MD. A comparison of treatment outcomes for adolescent community reinforcement approach participants with and without co-occurring problems. J Subst Abuse Treat. 2014 Apr;46(4):463-71. doi: 10.1016/j.jsat.2013.10.013. Epub 2013 Nov 11.
Results Reference
background
PubMed Identifier
26992083
Citation
Henderson CE, Wevodau AL, Henderson SE, Colbourn SL, Gharagozloo L, North LW, Lotts VA. An independent replication of the Adolescent-Community Reinforcement Approach with justice-involved youth. Am J Addict. 2016 Apr;25(3):233-40. doi: 10.1111/ajad.12366. Epub 2016 Mar 18.
Results Reference
background
PubMed Identifier
23580022
Citation
Meyers RJ, Roozen HG, Smith JE. The community reinforcement approach: an update of the evidence. Alcohol Res Health. 2011;33(4):380-8.
Results Reference
background
Citation
Fleming C, Haggerty K. Process and Outcomes Evaluation of Keys to Success. 2013.
Results Reference
background
PubMed Identifier
25264466
Citation
Almirall D, Nahum-Shani I, Sherwood NE, Murphy SA. Introduction to SMART designs for the development of adaptive interventions: with application to weight loss research. Transl Behav Med. 2014 Sep;4(3):260-74. doi: 10.1007/s13142-014-0265-0.
Results Reference
background
PubMed Identifier
27623005
Citation
Florence CS, Zhou C, Luo F, Xu L. The Economic Burden of Prescription Opioid Overdose, Abuse, and Dependence in the United States, 2013. Med Care. 2016 Oct;54(10):901-6. doi: 10.1097/MLR.0000000000000625.
Results Reference
background
Citation
Pain in the nation: The drug, alcohol and suicide crises and the need for a national resilience strategy. 2017. (Accessed September 25, 2018, at http://www.paininthenation.org/assets/pdfs/TFAH-2017- PainNationRpt.pdf.)
Results Reference
background
PubMed Identifier
22237030
Citation
Centers for Disease Control and Prevention (CDC). CDC grand rounds: prescription drug overdoses - a U.S. epidemic. MMWR Morb Mortal Wkly Rep. 2012 Jan 13;61(1):10-3.
Results Reference
background
Citation
Opioids. 2016. (at https://www.samhsa.gov/atod/opioids.)
Results Reference
background
PubMed Identifier
29033460
Citation
Case A, Deaton A. Mortality and morbidity in the 21st century. Brookings Pap Econ Act. 2017 Spring;2017:397-476. doi: 10.1353/eca.2017.0005.
Results Reference
background
Citation
Opioid epidemic. 2016. (Accessed September 25, 2018, at https://www.atg.wa.gov/opioid-epidemic.)
Results Reference
background
Citation
Schulenberg JE, Johnston LD, O'Malley PM, Bachman JG, Miech RA, Patrick ME. Monitoring the Future national survey results on drug use, 1975-2017: Volume II, College students and adults ages 19-55. Ann Arbor: Institute for Social Research, The University of Michigan; 2018.
Results Reference
background
PubMed Identifier
23410617
Citation
Jones CM. Heroin use and heroin use risk behaviors among nonmedical users of prescription opioid pain relievers - United States, 2002-2004 and 2008-2010. Drug Alcohol Depend. 2013 Sep 1;132(1-2):95-100. doi: 10.1016/j.drugalcdep.2013.01.007. Epub 2013 Feb 12.
Results Reference
background
PubMed Identifier
27552496
Citation
Banerjee G, Edelman EJ, Barry DT, Becker WC, Cerda M, Crystal S, Gaither JR, Gordon AJ, Gordon KS, Kerns RD, Martins SS, Fiellin DA, Marshall BD. Non-medical use of prescription opioids is associated with heroin initiation among US veterans: a prospective cohort study. Addiction. 2016 Nov;111(11):2021-2031. doi: 10.1111/add.13491. Epub 2016 Aug 23.
Results Reference
background
PubMed Identifier
29654539
Citation
Charak R, Ford JD, Modrowski CA, Kerig PK. Polyvictimization, Emotion Dysregulation, Symptoms of Posttraumatic Stress Disorder, and Behavioral Health Problems among Justice-Involved Youth: a Latent Class Analysis. J Abnorm Child Psychol. 2019 Feb;47(2):287-298. doi: 10.1007/s10802-018-0431-9.
Results Reference
background
Citation
Perez NM, Jennings WG, Baglivio MT. A path to serious, violent, chronic delinquency: The harmful aftermath of adverse childhood experiences. Crime & Delinquency 2018;64:3-25.
Results Reference
background
PubMed Identifier
20235445
Citation
Abbott PJ. A review of the community reinforcement approach in the treatment of opioid dependence. J Psychoactive Drugs. 2009 Dec;41(4):379-85. doi: 10.1080/02791072.2009.10399776.
Results Reference
background
PubMed Identifier
15072802
Citation
Roozen HG, Boulogne JJ, van Tulder MW, van den Brink W, De Jong CA, Kerkhof AJ. A systematic review of the effectiveness of the community reinforcement approach in alcohol, cocaine and opioid addiction. Drug Alcohol Depend. 2004 Apr 9;74(1):1-13. doi: 10.1016/j.drugalcdep.2003.12.006.
Results Reference
background
PubMed Identifier
16169159
Citation
Carroll KM, Ball SA, Nich C, Martino S, Frankforter TL, Farentinos C, Kunkel LE, Mikulich-Gilbertson SK, Morgenstern J, Obert JL, Polcin D, Snead N, Woody GE; National Institute on Drug Abuse Clinical Trials Network. Motivational interviewing to improve treatment engagement and outcome in individuals seeking treatment for substance abuse: a multisite effectiveness study. Drug Alcohol Depend. 2006 Feb 28;81(3):301-12. doi: 10.1016/j.drugalcdep.2005.08.002. Epub 2005 Sep 28.
Results Reference
background
PubMed Identifier
27887006
Citation
Goossens I, Nicholls TL, Torchalla I, Brink J, de Ruiter C. The Perceived Impact of Trauma-Focused Research on Forensic Psychiatric Patients With Lifetime Victimization Histories. J Empir Res Hum Res Ethics. 2016 Oct;11(4):334-345. doi: 10.1177/1556264616670769. Epub 2016 Nov 25.
Results Reference
background
Citation
Catalano RF, Park J, Harachi TW, Haggerty KP, Abbott RD, Hawkins JD. Mediating the effects of poverty, gender, individual characteristics, and external constraints on antisocial behavior: A test of the social development model and implications for developmental life-course theory. In: Farrington DP, ed. Advances in criminological theory: Vol 14. New Brunswick, NJ: Transaction; 2005:99-123.
Results Reference
background
Citation
Catalano RF, Hawkins JD. The social development model: A theory of antisocial behavior. In: Hawkins JD, ed. Delinquency and crime: Current theories. New York: Cambridge University Press; 1996:149-97.
Results Reference
background
Citation
Hirschi T. Causes of delinquency. Berkeley, CA: University of California Press; 1969.
Results Reference
background
Citation
Bandura A. Social learning theory. Englewood Cliffs, NJ: Prentice Hall; 1977.
Results Reference
background
Citation
Sutherland EH. Development of the theory [Private paper published posthumously]. In: Schuessler K, ed. Edwin Sutherland on analyzing crime. Chicago: University of Chicago Press; 1973:13-29.
Results Reference
background
Citation
R.L. M. The current state of differential association theory. Crime and Delinquency 1988;34:277-306.
Results Reference
background
PubMed Identifier
10396792
Citation
Catalano RF, Gainey RR, Fleming CB, Haggerty KP, Johnson NO. An experimental intervention with families of substance abusers: one-year follow-up of the focus on families project. Addiction. 1999 Feb;94(2):241-54. doi: 10.1046/j.1360-0443.1999.9422418.x.
Results Reference
background
Citation
Fleming CB, Catalano RF, Oxford ML, Harachi TW. A test of generalizability of the social development model across gender and income groups with longitudinal data from the elementary school developmental period. Journal of Quantitative Criminology 2002;18:423-39.
Results Reference
background
PubMed Identifier
29687524
Citation
Ford JD, Grasso DJ, Greene CA, Slivinsky M, DeViva JC. Randomized clinical trial pilot study of prolonged exposure versus present centred affect regulation therapy for PTSD and anger problems with male military combat veterans. Clin Psychol Psychother. 2018 Sep;25(5):641-649. doi: 10.1002/cpp.2194. Epub 2018 Apr 23.
Results Reference
background
PubMed Identifier
23611076
Citation
Ford JD, Chang R, Levine J, Zhang W. Randomized clinical trial comparing affect regulation and supportive group therapies for victimization-related PTSD with incarcerated women. Behav Ther. 2013 Jun;44(2):262-76. doi: 10.1016/j.beth.2012.10.003. Epub 2012 Nov 5.
Results Reference
background
PubMed Identifier
23428165
Citation
Ford JD, Grasso DJ, Hawke J, Chapman JF. Poly-victimization among juvenile justice-involved youths. Child Abuse Negl. 2013 Oct;37(10):788-800. doi: 10.1016/j.chiabu.2013.01.005. Epub 2013 Feb 19.
Results Reference
background
PubMed Identifier
22233243
Citation
Ford JD, Steinberg KL, Hawke J, Levine J, Zhang W. Randomized trial comparison of emotion regulation and relational psychotherapies for PTSD with girls involved in delinquency. J Clin Child Adolesc Psychol. 2012;41(1):27-37. doi: 10.1080/15374416.2012.632343.
Results Reference
background
PubMed Identifier
22035986
Citation
Ford JD, Steinberg KL, Zhang W. A randomized clinical trial comparing affect regulation and social problem-solving psychotherapies for mothers with victimization-related PTSD. Behav Ther. 2011 Dec;42(4):560-78. doi: 10.1016/j.beth.2010.12.005. Epub 2011 Apr 16.
Results Reference
background
Citation
www.wsipp.wa.gov/BenefitCost?topicId=1 Accessed 3-2-2019.
Results Reference
background
Links:
URL
http://www.samhsa.gov/atod/opioids
Description
Information about opioids
URL
https://www.brookings.edu/bpea-articles/mortality-and-morbidity-in-the-21st-century.)
Description
Mortality and morbidity in the 21st century
URL
https://www.atg.wa.gov/opioid-epidemic
Description
The opioid epidemic
URL
https://www.cdc.gov/drugoverdose/epidemic/index.html
Description
Understanding the opioid epidemic
URL
http://www.wsipp.wa.gov/BenefitCost?topicId=1
Description
Benefit-Cost Analysis

Learn more about this trial

Preventing OUD in Justice-Involved Youth

We'll reach out to this number within 24 hrs